Kobayashi Pharmaceutical Co(JP:4967)
¥7,025.00-50.00 (-0.71%)
JP:4967
Kobayashi Pharmaceutical Co earnings date
¥7,025.00
At close:-50.00 (-0.71%)
Want to see JP:4967 full AI Analyst Report?
Kobayashi Pharmaceutical Co (4967) Q2 2022 Earnings Report
0 Followers
JP:4967 Q2 2022 EPS Results
- Actual EPS
- JPY 54.68
- Consensus EPS
- JPY 7,629.77
- Beat/Miss
- Missed by -JPY 7,575.09
- One Year Ago EPS
- JPY 54.42
JP:4967 Q2 2022 Revenue Results
- Actual Revenue
- JPY 38.62B
- Expected Revenue
- JPY 6.00T
- Beat/Miss
- Missed by -JPY 5.96T
- YoY Revenue Growth
- +4.99%
Earnings Announcement Details
- Quarter
- Q2 2022
- Date
- 08/03/2022
- Time
- TBA
- Conference Call
- Wednesday, August 3, 2022
JP:4967 Upcoming Earnings
Kobayashi Pharmaceutical Co's next earnings date is estimated for February 16, 2027, based on past reporting schedules.
Q2 2022 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2022 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2022 Earnings Call Summary
No earnings call summary is available for this earnings event.
JP:4967 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 16, 2027 | 2026 (Q4) | 43.05- | -42.41 | ― | ― |
| Nov 10, 2026 | 2026 (Q3) | 64.5788.80 | 48.99 | 81.26% (+39.81) | |
| Aug 06, 2026 | 2026 (Q2) | 24.211.34 | 20.75 | -93.54% (-19.41) | |
| May 08, 2026 | 2026 (Q1) | 5.3813.95 | 21.86 | -36.18% (-7.91) | |
| Feb 10, 2026 | 2025 (Q4) | 81.80-42.41 | 63.52 | -166.77% (-105.93) | |
| Nov 11, 2025 | 2025 (Q3) | 43.9348.99 | 52.58 | -6.83% (-3.59) | |
| Aug 05, 2025 | 2025 (Q2) | 24.0320.75 | 6.19 | 235.22% (+14.56) | |
| May 09, 2025 | 2025 (Q1) | 50.0221.86 | 13.13 | 66.49% (+8.73) | |
| Feb 10, 2025 | 2024 (Q4) | 78.1363.52 | 56.55 | 12.33% (+6.97) | |
| Nov 08, 2024 | 2024 (Q3) | 82.3752.58 | 100.29 | -47.57% (-47.71) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed

